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REVIEW
Abstract: Fluctuating Parkinson’s disease (PD) represents a clinical management challenge. 
The primary utility of levodopa in patients with PD is moderated by the “wearing off” phenomena 
seen with long-term use. COMT inhibitors slow down the rapid metabolism of levodopa, result-
ing in a more-sustained response to dopaminergic therapy. Tolcapone is a selective, reversible 
catechol-O-methyltransferase (COMT) inhibitor, shown to have both peripheral and central 
effects. In clinical trials, tolcapone has been shown to reduce “off” time, increase “on” time, 
improve patient and clinician assessments of disease severity, and improve patient quality of life. 
In a SWITCH study, tolcapone was associated with greater duration of “on” time than remaining 
on entacapone. Adverse effects of tolcapone are related to the class, with the exception of rare 
cases of hepatotoxicity. Tolcapone has been recently reintroduced on the European market and 
recent guidance from the US Food and Drug Administration has reduced the hepatic monitoring 
requirements for patients initiating tolcapone therapy. With proper monitoring, tolcapone is an 
effective, well-tolerated drug useful in the management of patients with ﬂ  uctuating PD.
Keywords: Parkinson’s disease; tolcapone, COMT inhibitors, drug therapy, safety, 
tolerability
Introduction
Parkinson’s disease (PD) affects about 1% of adults over the age of 60; as industrial 
societies age, the prevalence of PD is expected to increase (Olanow et al 2001). In the 
US alone, an estimated 60 000 new cases of idiopathic PD, characterized by resting 
tremor, rigidity, and bradykinesia, are diagnosed each year. 
The dopamine precursor levodopa has been a mainstay of PD treatment for almost 
40 years (Cotzias et al 1967). In fact, good response to levodopa helps distinguish 
idiopathic PD from other, similar movement disorders (Hughes et al 1992). However, 
levodopa therapy is eventually complicated by motor ﬂ  uctuations, including “wearing 
off” and “on-off” phenomena (Fahn 1999). Drug-induced dyskinesias, including chorea 
and dystonia, also occur with long-term levodopa therapy in most patients, ultimately 
reducing quality of life and causing signiﬁ  cant disability (Chapuis et al 2005). 
Levodopa is routinely administered in combination with a decarboxylase inhibi-
tor, many of which are available as co-formulations under a variety of brand names 
in the US and Europe. Decarboxylase inhibitors prevent conversion of levodopa to 
dopamine in the peripheral circulation, thereby allowing more levodopa to cross 
the blood–brain barrier into the central nervous system (CNS) (Olanow et al 2001). 
Decarboxylase inhibitors also reduce nausea and vomiting that can occur due to 
stimulation of dopamine receptors in the area postrema that are not protected by the 
blood–brain barrier.
By blocking the decarboxylase route of metabolism, circulating levodopa is primarily 
metabolized by catechol-O-methyltransferase (COMT) to 3-O-methyldopa (3-OMD) 
(Kaakkola 2000). COMT inhibitors in combination with levodopa/decarboxylase 
inhibitor preparations are associated with an increase of CNS bioavailability of 
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levodopa. Theoretically, COMT inhibitors that are active 
in the CNS would also reduce central metabolism of both 
levodopa and dopamine.
Tolcapone is a potent, selective reversible inhibitor of 
COMT (Zurcher et al 1990). Preclinical models showed 
tolcapone effectively inhibited COMT in the gut, brain, 
and liver (Borgullya et al 1991; Da Prada et al 1991; 
Zurcher et al 1991). In clinical trials, it has been shown 
to be effective adjunctive therapy for patients who are not 
obtaining optimal response to levodopa-based therapy. 
In 1998, 3 cases of acute hepatitis leading to mortality 
among patients receiving tolcapone led to the temporary 
suspension of availability of tolcapone in the EU (EMEA 
2004), as well as stringent monitoring requirements in 
the US (FDA 1998). Since then, the compound has been 
returned to the EU approved drugs list, and the US Food 
and Drug Administration (FDA) requirements for liver 
monitoring have been eased (FDA 2006). This article will 
review pertinent research related to appropriate selection 
of candidates for tolcapone use. 
Clinical pharmacology of tolcapone
Pharmacokinetics
Tolcapone displays linear pharmacokinetics, independent 
of levodopa/carbidopa administration, and independent of 
sex, age, weight, or race (Tasmar PI 2006). Oral tolcapone 
is rapidly absorbed, with a tmax of about 2 hours and an 
elimination half-life (t1/2) of about 2 to 3 hours in both single 
doses and at the recommended dosing frequency of three 
times a day, both alone and in combination with levodopa 
and a decarboxylase inhibitor (Table 1) (Dingemanse, Jorga, 
Schmitt, et al 1995; Dingemanse, Jorga, Zurcher, et al 1995; 
Dingemanse et al 1996; Jorga et al 1997). Tolcapone displays 
high plasma binding (>99.9%), mainly to serum albumin, 
leading to a limited volume of distribution at steady state 
(9L). The oral bioavailability of tolcapone is approximately 
65%, which is decreased by about 10% to 20% if taken 
1 hour before or 2 hours after a meal. Tolcapone can be taken 
without regard to meals (Tasmar PI 2006). 
Tolcapone is extensively metabolized, primarily by 
glucuronidation into an inactive conjugate, with only 
0.5% of the administered dose excreted unchanged in 
urine (Jorga et al 1999). In patients with moderate cir-
rhotic liver disease (Child-Pugh Class B), clearance and 
volume of distribution of unbound tolcapone was reduced 
by almost 50% (Jorga et al 1998). However, no clinically 
signiﬁ  cant changes in pharmacokinetics were noted among 
patients with noncirrhotic liver disease. Tolcapone therapy 
should not be initiated in patients with active liver dis-
ease or who have elevated transaminase values (Tasmar 
PI 2006). Tolcapone pharmacokinetics are not altered by 
renal impairment, although caution is warranted among 
patients with severe renal dysfunction.
Pharmacodynamics
At clinically relevant concentrations, tolcapone inhibited 
COMT activity in in vitro assays of human liver, duodenum, 
kidney, and lung tissue (De Santi et al 1998). Tolcapone 
also inhibited COMT activity in erythrocytes among healthy 
volunteers receiving single or multiple doses of the drug 
(Dingemanse, Jorga, Schmitt, et al 1995; Dingemanse, Jorga, 
Zurcher, et al 1995; Dingemanse et al 1996; Jorga et al 1997). 
This dose-dependent inhibition was rapid, occurring within 
2 hours of administration, and reversible, with ≥80% inhibi-
tion occurring with a single 200 mg dose. 
Tolcapone may also block COMT activity in the CNS 
(Ceravolo et al 2002). A study of 12 patients with PD using 
positron emission tomography and radiolabelled ﬂ  uorodopa 
Table 1 Pharmacokinetic parameters (mean values) of oral tolcapone (TOL) in healthy volunteers.a TOL was administered alone or 
in combination with levodopa/benserazide 100 mg/25 mg (L-Dopa/Ben) or levodopa/carbidopa 100 mg/25 mg (L-Dopa/Car)
  TOL alone    TOL + L-Dopa/Ben  TOL + L-Dopa/Car     
Pharmacokinetic   100 mg sd  200 mg sd  100 mg sd  200 mg sd  100 mg sd  200 mg sd  100 mg tid  200 mg tid
parameter (n=5–6)  (n=5–6)  (n=6)  (n=6)  (n=6)  (n=6)  (n=6)b (n=6)b
Cmax  (mg/L)  4.6  6.3  4.5  7.5  2.8 5.9  3.5   6.4
tmax  (h)  1.7  1.8  0.7  1.9  1.6 3.1  2.0   1.8
AUC∞ (mg • h/L)  12.2  18.5  10.2  24.0  12.7  25.1  13.0c   26.7 c
T½  (h)  2.0  2.1  1.9  2.0  2.2 2.6  2.2   3.1
Notes: avolunteers were aged 18–40 y, 19–35 y, or 55–75 y; bvalues given are those for day 7; cAUC from 0–6 h.
Abbreviations: AUC∞, area under the plasma concentration-time curve from time zero to inﬁ  nity; Cmax, maximum plasma concentration; sd, single dose; t½, elimination 
half-life; tid, three times daily; tmax, time to Cmax.Clinical Interventions in Aging 2006:1(4) 319
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showed evidence of central blockade of central COMT 
activity compared with placebo. 
Mechanism of action – impact on 
levodopa pharmacokinetics
The mechanism of action of tolcapone is based on alter-
ing levodopa pharmacokinetics, as well as reducing the 
levodopa metabolite 3-OMD. Tolcapone prolongs the t1/2 
of levodopa from approximately 2 to 3.5 hours (Davis et 
al 1995a; Tasmar PI 2006). This results in an approximate 
doubling of levodopa relative bioavailability (area under 
curve). However, Cmax or tmax.of levodopa are unaffected. 
Studies in healthy volunteers and Parkinson’s disease patients 
have conﬁ  rmed that the maximal effect occurs with 100 mg 
to 200 mg tolcapone. Plasma levels of 3-OMD are markedly 
and dose-dependently decreased by tolcapone when given 
with levodopa/carbidopa. 
Clinical trials of tolcapone
Effects of COMT inhibition are seen shortly after 
administration, allowing for clinical efﬁ  cacy of tolcapone 
to be investigated in single-dose trials where patients were 
observed in a controlled setting for several hours after acute 
administration. In a dose-ranging study, single doses of 
tolcapone were found to extend the time antiparkinsonian 
effects of levodopa/carbidopa by about 70% (Roberts et al 
1994). A separate study using levodopa/benserazide con-
curred with this ﬁ  nding, with tolcapone-treated patients 
displaying approximately 1 hour of extra “on” time versus 
placebo (Limousin et al 1995). A dose-ranging study of 
levodopa/carbidopa plus the monoamine oxidase inhibitor se-
legiline found that the addition of a single dose of tolcapone, 
ranging from 50 mg to 800 mg, prolonged the antiparkinso-
nian effects of levodopa/carbidopa (Davis et al 1995b).
In a study of tolcapone pharmacokinetics following 
6 weeks of open-label therapy, improvements were seen 
in the Uniﬁ  ed Parkinson’s Disease Rating Scale (UPDRS) 
at 7 time points following administration (Yamamoto et al 
1997).
The approval of tolcapone in the US and Europe was 
based on evidence from 2 multicenter, randomized, dou-
ble-blind, placebo-controlled clinical trials in patients with 
levodopa-induced motor ﬂ  uctuations (Baas et al 1997. Rajput 
et al 1997). 
In the pivotal trial conducted in Europe, 177 patients were 
randomized 1:1:1 to receive tolcapone 100 mg or 200 mg 
three times daily (tid), or placebo (containing riboﬂ  avin to 
mimic urinary discoloration seen as a harmless side effect 
of tolcapone) (Baas et al 1997). Levodopa could be adjusted 
according to patient response and adverse effects up until 
2 weeks prior to the 3-month efﬁ  cacy endpoint determination. 
Levodopa could not be increased above baseline prior to 
the 3-month time point. “On” time increased by 21.3% and 
20.6% from baseline with 100 mg and 200 mg tolcapone 
(p<0.01 versus placebo). “Off” time decreased by 31.5% 
with the 100mg dose (p<0.5) and 26.2% with the 200 mg 
dose (p=NS). Tolcapone 200 mg tid was superior to placebo 
in UPDRS motor function score during “on” time. Tolcapone 
therapy was also associated with a statistically signiﬁ  cant 
reduction in levodopa doses, with larger dose reductions 
seen with the 200 mg tid dose. 
There were 202 patients enrolled in a similarly designed 
study conducted in North America (Rajput et al 1997). Total 
levodopa doses were signiﬁ  cantly reduced in both tolcapone 
dose arms (p<0.01), as well as number of mean daily levo-
dopa doses. In this trial, patients receiving tolcapone showed 
decreases in “off” time; however only tolcapone 200 mg 
tid reached statistical signiﬁ  cance (p<0.01). At 3 months, a 
mean reduction in “off” time of 3.25 hours was noted with 
tolcapone 200 mg tid. Investigators’ global assessment (IGA) 
indicated that 68% of patients receiving tolcapone 100 mg tid, 
and 95% of those receiving tolcapone 200 mg tid displayed 
a reduced “wearing off” effect, compared with 37% of pa-
tients receiving placebo (p<0.01). Patients were allowed to 
continue on their assigned therapy for up to 12 months after 
randomization. For those that reached the 12-month time 
point, the IGA of overall efﬁ  cacy showed improvement in 
80% of patients receiving tolcapone 100 mg tid, and 88% 
of patients receiving tolcapone 200 mg tid, compared with 
37% of patients receiving placebo. In addition, reductions in 
levodopa dosages noted at 3 months were maintained through 
the 12-month completion of the trial (Figure 1). 
The above trials were included in an analysis of treatment 
for levodopa-induced motor ﬂ  uctuations recently completed 
by a committee of the American Academy of Neurology 
(AAN) (Pahwa et al 2006). The committee recognized tol-
capone as having utility in reducing “off” time. Additional 
clinical trials of tolcapone that were not reviewed by the 
AAN committee have also been completed in patients with 
ﬂ  uctuating PD, including a head-to-head study with the 
COMT inhibitor entacapone, as well as studies in patients 
with stable PD. 
Tolcapone substantially increased “on” time and de-
creased “off” time in a study of 215 patients with ﬂ  uctuating 
PD (Adler et al 1998). Patients were randomized to tolcapone Clinical Interventions in Aging 2006:1(4) 320
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100 mg, 200 mg, or matching placebo. The onset of response 
to tolcapone was rapid; improvements were seen at the ﬁ  rst 
study visit 2 weeks after initiation of therapy. By week 6, 
on time had increased by more than 2 hours, and off time 
had decreased to a similar extent in both tolcapone groups 
(Figure 2) (p<0.001 versus placebo). The improvement 
noted represented an approximately 38% improvement in off 
time. The total daily dose of levodopa required for patients 
receiving tolcapone 100mg tid was reduced by 23% (p<0.01 
versus placebo). Patients receiving tolcapone 200 mg tid re-
duced their levodopa requirements by 29% (p<0.001 versus 
placebo). The total number of daily doses of levodopa was 
reduced signiﬁ  cantly in both tolcapone groups. 
A 6-week placebo-controlled trial of tolcapone 50 mg, 
200 mg, and 400 mg tid reported results from 151 patients 
(Kurth et al 1997). In this trial, investigators also conducted 
10-hour evaluations of motor ﬂ  uctuations at baseline and 
at the 6-week study visit. During this evaluation, patients 
were scored every 30 minutes for “off” time, “on” time, 
and “on” time with dyskinesia. The primary endpoints were 
changes in investigator-rated measurements of “on/off” time 
at the 6-week evaluation from baseline, as well as changes 
in the UPDRS motor subscale score. All three dosages of 
tolcapone reduced “off” time by about 40% from baseline 
(p<0.01 for all tolcapone arms vs placebo). Tolcapone also 
signiﬁ  cantly increased “on” time for the 50 mg (p<0.05), 
200 mg (p<0.01) and 400 mg (p<0.01) groups compared with 
placebo. In this study, there was no difference between the 
three tolcapone arms in “on” time. Patient diaries completed 
during the 6-week study supported the 10-hour evaluation 
ﬁ  nding of decreased “off” time and increased “on” time. The 
change in the area under the curve of mean UPDRS motor 
subscale scores favored all tolcapone doses (p<0.05). Patients 
receiving tolcapone also reported signiﬁ  cant decreases in 
total levodopa dosing (p<0.01); reduction in the number of 
daily levodopa doses was statistically signiﬁ  cant for patients 
receiving tolcapone 200 mg and 400 mg tid. 
A European-Australian collaborative group reported a 
6-week placebo-controlled trial of tolcapone 50 mg, 200 mg, 
and 400 mg tid versus placebo among 154 patients in a 
study that included a 2-week single-blind placebo run-in 
phase (Myllyla et al 1997). The primary efﬁ  cacy analysis 
Figure 1 Reductions in levodopa dosage seen at the end of 3 months were 
maintained throughout treatment in the patients who received tolcapone. 
Copyright © 1997. Permission requested from Rajput AH, Martin W, Saint-Hilaire 
MH, et al. 1997. Tolcapone improves motor function in parkinsonian patients with 
the “wearing-off” phenomenon: a double-blind, placebo-controlled, multicenter 
trial. Neurology, 49:1066-71.
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Figure 2 Increased ‘on’ time, reduced ‘off’ time with tolcapone. Copyright © 1998. Permission requested from Adler CH, Singer C, O’Brien C, et al. 1998. 
Randomized, placebo-controlled study of tolcapone in patients with ﬂ  uctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol, 55:1089-95.
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was patient diary assessments of “on” and “off” time. 
In this study, improvements were seen in both primary 
efﬁ  cacy variables. All tolcapone doses were statistically 
signiﬁ  cantly more effective than placebo in increasing “on” 
time; however, only tolcapone 200 mg tid reached statisti-
cal signiﬁ  cance versus placebo in reducing “off” time. The 
tolcapone 200 mg tid dose resulted in a 34% increase in 
“on” time and a 42% reduction on “off” time from baseline 
values. The greatest reduction in total levodopa daily dosage 
was also greatest in the tolcapone 200 mg tid group (p<0.01 
versus placebo). The IGA for “wearing off” and symptom 
severity were both statistically signiﬁ  cant for all tolcapone 
doses (p<0.05 versus placebo).
The UPDRS motor scores during off-period and the per-
centage of off time improved signiﬁ  cantly using tolcapone in 
a small study of 40 patients (Shan et al 2001). However gait 
analysis did not conﬁ  rm these ﬁ  ndings in this trial. Second-
ary analyses of other UPDRS subscales of total scores in the 
above studies did not demonstrate statistically signiﬁ  cant 
improvements over placebo (Kurth et al 1997; Myllyla et al 
1997; Rajput et al 1997; Adler et al 1998; Shan et al 2001). 
Other secondary analysis of health-related quality of life 
found an improvement in one study (Baas et al 1997), but 
not another (Adler et al 1998). 
Comparator trials
One other COMT inhibitor, entacapone, is approved for use 
in the US and Europe for patients with symptoms of levo-
dopa “wearing off” (Comtan PI 2006). Recently, data were 
presented from the SWITCH study aimed at determining 
if switching from entacapone to tolcapone might improve 
patient outcomes (SWITCH 2006). This was a double-blind, 
active-control study conducted at 32 centers in Europe and 
the US, enrolling 150 individuals who had 3 or more hours 
of “off” time despite optimized entacapone therapy. Patients 
were randomized to receive either entacapone 200 mg with 
each levodopa dose, or tolcapone 100 mg tid. Treatment 
duration was 3 weeks. In the per protocol analysis, a sta-
tistically signiﬁ  cant greater proportion of patients switched 
to tolcapone had at least 3 hours a day of additional “on” 
time (p=0.018). Both groups saw an increase in “on” time; 
however, the tolcapone had a mean increase of 0.86 hours 
more than the entacapone group (p=0.042). More patients 
on tolcapone were judged to have a moderate or marked 
improvement on the IGA (27% for entacapone vs 40% for 
tolcapone; p=not signiﬁ  cant). More patients responded to 
tolcapone, as deﬁ  ned by both at least 1 hour/day improve-
ment in “on” time and an IGA rating of moderate or marked 
improvement (p=0.051). There was no difference between 
groups in the frequency or severity of adverse events, 
including dyskinesia, or in the incidence of liver enzyme 
abnormalities.
Other evidence in favor of the increased efﬁ  cacy of 
tolcapone over entacapone was reported in a case study 
series of 40 patients who were switched from tolcapone to 
entacapone (Onofrj et al 2001). Patients had been switched 
either due to intolerability or due to the temporary suspension 
of tolcapone availability in Europe. After 3 to 6 months of 
levodopa therapy adjustments, all patients received entaca-
pone for 3 months. The authors reported that levodopa daily 
dosage was signiﬁ  cantly reduced by both tolcapone and en-
tacapone. “On” time was increased by 15% during tolcapone 
treatment (p<0.05), and by 8% during entacapone treatment. 
“Off” time was decreased by 16% during tolcapone and by 
7% during entacapone treatment.
Tolcapone also appears to have greater long-term ben-
eﬁ  ts compared with entacapone, according to an analysis 
conducted of data collected from 2 groups of patients en-
rolled in parallel long-term tolerability and efﬁ  cacy studies 
of tolcapone and entacapone (Factor et al 2001). The entry 
criteria, efﬁ  cacy and tolerability analyses, and data collec-
tion points for the two trials were similar. In this analysis, 
tolcapone was more effective in lowering UPDRS motor and 
complication subscores, as well as duration of “off” time, 
and total levodopa doses. Improvements seen in UPDRS 
motor scores and change in levodopa dose remained below 
baseline level for 36 months in the tolcapone group; those 
same scores climbed above baseline in the entacapone group 
from the 6-month study visit onward.
Tolcapone 100 mg tid was compared with add-on 
therapy with the dopamine agonist pergolide (Koller 
et al 2001). There was no placebo-controlled arm in this 
trial; however, both therapies showed similar efﬁ  cacy in 
reducing “off” time, increasing “on” time, reducing total 
daily levodopa dosage, or in UPDRS scores, and IGAs. 
Tolcapone was more effective than pergolide in improving 
a quality of life measure, the PDQ-39 scale, at 12 weeks 
(p=0.0005). 
An open-label comparative trial of tolcapone 200 mg tid 
versus the dopamine agonist bromocriptine was conducted 
in 146 PD patients (TSG 1999). At the end of 8 weeks, both 
treatment groups showed similar results in “on” time, “off” 
time, and UPDRS subscale scores. Because bromocriptine 
must be titrated upward over a period of time, patients 
assigned to tolcapone showed greater improvements early 
in the course of therapy. The mean total daily levodopa Clinical Interventions in Aging 2006:1(4) 322
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dosage decreased by 16.5% in the tolcapone-treated 
patients, compared with 4% among patients receiving 
bromocriptine (p<0.01). In the tolcapone group, this re-
duction was achieved as early as week 1 and was almost 
complete by week 4.
Trials in stable PD
All of the trials reviewed above were conducted among 
patients with ﬂ  uctuating PD associated with the levodopa 
“wearing off” syndrome. Tolcapone is approved for this in-
dication in the US and Europe. Additional studies have been 
conducted to determine if tolcapone can provide beneﬁ  ts for 
patients with stable PD on levodopa therapy.
Tolcapone 100 mg and 200 mg tid were evaluated in 
patients on stable levodopa therapy in a 12-week crosso-
ver study (Suchowersky et al 2001). All patients received 
tolcapone 100 mg tid for 4 weeks, then were randomly 
assigned to either continue on that dosage or to receive 
tolcapone 200 mg tid. At week 8, therapy was switched to 
the alternate dosage level in a double-blind fashion. During 
the 4-week open-label run-in, tolcapone 100 mg tid resulted 
in improvements in IGAs among 76% of patients. In addi-
tion, the mean total daily levodopa dose and mean UPDRS 
subscale scores decreased signiﬁ  cantly (p<0.001 for all 
measures compared with baseline). During the double-blind 
treatment period, 61% of patients showed improvements 
in their IGA at either or both dosages. Other efﬁ  cacy vari-
ables changed minimally; there was no difference between 
tolcapone dosages.
A double-blind, placebo-controlled trial investigated 
the effect of tolcapone 100 mg or 200 mg tid on activi-
ties of daily living and motor function in 298 patients 
with PD receiving levodopa but without motor fluctua-
tions (Waters et al 1998). At 6 months, both dosages of 
tolcapone produced significant reductions in the UPDRS 
subscales II and III and in the total score for subscales 
I to III. These improvements were maintained up to 
12-months. At 6 months, both tolcapone groups had 
significant decreases in levodopa dosage compared with 
placebo. Both tolcapone groups reported decreases in 
mean total daily dose of levodopa, while the placebo 
group had a mean increase.
Tolcapone 200 mg and 400 mg tid were studied in 
patients whose “wearing off” symptoms had been sta-
bilized by increasing their levodopa dosing (Dupont et 
al 1997). After a 1-week placebo run-in, patients were 
assigned to placebo or one of the tolcapone dosages. 
Levodopa dosage was reduced by 35% on day 1, then 
retitrated upward as required. After 6 weeks, the study 
was unblinded and the tolcapone groups crossed over to 
the other dose for exploratory purposes. Although not sta-
tistically different, both tolcapone groups showed greater 
reductions in levodopa dosage requirements compared 
with placebo. Tolcapone 200 mg tid showed statistically 
signiﬁ  cant improvement in the UPDRS subscale II (p<0.05 
versus placebo). 
Safety and tolerability of tolcapone
Hepatotoxicity
During post-marketing surveillance, 3 cases of fatal 
hepatotoxicity were reported in patients who were not 
properly monitored. As a result, new FDA guidelines 
for liver testing were established. This also prompted 
the sponsor to conduct a review of the tolcapone safety 
database, representing approximately 100 000 patient-
years of therapy (Watts and Kricorian 2005). Although 
underreporting of adverse events may have occurred, a 
total of 219 cases of hepatobiliary events were recorded. 
Most of these cases were mild transient elevations in liver 
function tests <3 times the upper limit of normal (ULN). 
Most cases were either asymptomatic or resolved without 
treatment interruption. Only 21 cases (0.001%) reported 
elevations in alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) >3 times ULN; the median time 
to this adverse event was 81 days. After new monitoring 
guidelines were in place, no deaths related to hepatotox-
icity occurred. In addition, asymptomatic elevations in 
liver function tests did not progress to acute hepatitis if 
treatment was withdrawn.
As a result of this analysis, the FDA has recently reduced 
the liver monitoring requirements for tolcapone use (FDA 
2006). The newly approved labeling states that serum glutam-
ic pyruvic transaminase (SGPT)/ALT and serum glutamic 
oxaloacetic transaminase (SGOT)/AST levels should be 
determined at baseline, as well as periodically (ie, every two 
to four weeks) for the ﬁ  rst six months of therapy. Periodic 
monitoring is recommended at intervals deemed clinically 
relevant after the ﬁ  rst 6 months of therapy. In addition, 
patients can remain on tolcapone therapy if liver enzymes 
are below 2 times ULN and/or do not display symptoms of 
liver toxicity.
Other adverse events
New or worsening dyskinesia is the most common adverse 
event associated with tolcapone therapy. Worsening of Clinical Interventions in Aging 2006:1(4) 323
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dyskinesia most commonly occurs at the start of tolcapone 
therapy, and may be moderated by optimizing levodopa dos-
ages (Baas et al 1997; Rajput et al 1997; Adler et al 1998). 
Dyskinesia and other dopaminergic adverse events are most 
likely due to the increase in levodopa concentrations that 
provide the rationale for tolcapone use. 
Diarrhea is the most commonly reported nondopamin-
ergic adverse event reported in clinical trials (Rajput et al 
1997; Waters et al 1997; Adler et al 1998). Table 2 lists the 
common adverse events reported by the manufacturer in 
clinical trials. 
In the comparative trial with entacapone, the frequency 
and severity of adverse events was similar between the two 
medications (SWITCH 2006). In the trial comparing tolca-
pone with pergolide, tolcapone was associated with reduced 
risk of nondyskinesia adverse events (59% vs 77% for per-
golide; p=0.001) (Koller et al 2001). Dyskinesia occurred in 
34% of tolcapone recipients and 25% of pergolide recipients. 
Incidence of nausea was also substantially higher with per-
golide therapy (35%) compared with tolcapone (20%). In 
the trial comparing tolcapone with bromocriptine, nausea, 
orthostatic complaints, hallucinations, and peripheral edema 
were reported more often among bromocriptine patients, 
while muscle cramps, dystonia, and dry mouth were reported 
more often among tolcapone recipients (TSG 1999). 
Discussion
Tolcapone is an effective agent that can help improve the 
efﬁ  cacy of levodopa-based therapy in patients with PD. 
It is especially useful, and indicated for, patients who are 
experiencing “wearing off” motor ﬂ  uctuations from their 
levodopa therapy. Beneﬁ  ts of tolcapone have also been 
demonstrated among patients on stable levodopa therapy 
who have not yet begun to display motor ﬂ  uctuations. 
There is also increasing interest in determining whether 
early administration of a COMT inhibitor (ie, at the ﬁ  rst 
use of levodopa) might reduce the risk of eventual motor 
complications (Olanow et al 2001). The primary adverse 
effect of tolcapone is dyskinesia, which is more of a prob-
lem among patients who present with dyskinesia prior to 
initiation of tolcapone therapy. Immediate reductions in 
levodopa dosages between 15% and 30% may be warranted 
to obviate this concern. 
The goal of providing clinical beneﬁ  ts for PD patients 
over the longest period of time without undue adverse events 
remains elusive at best. The determination of when to begin 
levodopa-based therapy in patients with PD is complex. It 
is generally recommended that any pharmacotherapy not be 
initiated until patients begin to show functional deterioration 
(Olanow et al 2001). Levodopa therapy may be delayed with 
early use of dopamine agonists in younger patients; however, 
eventually all patients receiving dopamine agonist therapy 
will require levodopa supplementation. Levodopa has the 
advantage of being almost universally efﬁ  cacious among 
patients with idiopathic PD. However, the long-term outcome 
of levodopa-based therapy is clouded by the “wearing off’ 
phenomena. Future clinical research is warranted to deter-
mine whether early use of COMT inhibitors like tolcapone 
can delay the onset of levodopa-associated adverse effects. 
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